Table 2.

Antiangiogenics and efficacy according to hypertension development

Abbreviations: 5-FU, 5-fluorouracil; AVADO, Avastin and Docetaxel; AVAiL, Avastin in Lung Cancer; AVOREN, Avastin and Roferon in Renal Cell Carcinoma; BP, blood pressure; CALGB, Cancer and Leukemia Group B; DBP, diastolic blood pressure; DCR, disease control rate; ECOG, Eastern Cooperative Oncology Group; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; HR, hazard ratio; HTN, hypertension; IFL, irinotecan, leucovorin, and 5-fluorouracil; IFN, interferon; LV, leucovorin; NSCLC, non-small cell lung cancer; OS, overall survival; PC, paclitaxel plus carboplatin; PCB, paclitaxel, carboplatin, and bevacizumab; PCC, paclitaxel, carboplatin, and cediranib; PFS, progression-free survival; RIBBON, Regimens in Bevacizumab for Breast Oncology; RR, response rate; SaiL, Safety of Avastin in Lung Cancer; SBP, systolic blood pressure; TTP, time to progression; XELIRI, capecitabine and irinotecan; XELOX, capecitabine and oxaliplatin.